Terneurine

Quick links to important sections

Terneurine

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Terneurine

Property Description
Active ingredient Thiamine, Pyridoxine, Cyanocobalamin
Form Oral tablets, Capsules, Injectable solution
Pharmacological class B-complex vitamin, Nutritional supplement
General purpose Nutrient repletion, Metabolic support
Origin Synthetic/Derived

Terneurine is classified as a nutritional supplement and a combination product belonging to the pharmacological class of B-complex vitamins. This preparation is specifically formulated to supply multiple essential water-soluble vitamin compounds required for fundamental physiological processes, acting as an agent for nutrient repletion. The primary purpose of this B-complex vitamin is to maintain or restore adequate levels of these micronutrients within the body, which are often depleted due to dietary factors or increased metabolic demand. The formulation is clinically recognized for its potential to support nerve health due to its concentrated vitamin B content.

Composition: What Vitamin B Substances are in Terneurine?

Terneurine is typically composed of key Vitamin B Substances, including Thiamine (Vitamin B1), Pyridoxine (Vitamin B6), and Cyanocobalamin (Vitamin B12), which are frequently synthetic or derived compounds optimized for pharmaceutical use. These active ingredients are formulated into various high-level dosage forms, predominantly as oral tablets or capsules. The product may also be available as an injectable solution for administration via the intramuscular or intravenous route, using an aqueous base or vehicle for direct systemic delivery when necessary. These vitamins are essential components in human nutrition. The availability of both oral and injectable preparations is a distinguishing feature, offering flexibility in addressing different degrees of micronutrient deficiency.

General Benefit: Why is Terneurine Used?

The general benefit of Terneurine lies in its ability to support essential biological functions by providing necessary metabolic cofactors for cellular activity. Supplying these Vitamin B Substances is crucial for facilitating neuro-physiological support, which helps maintain the health and function of the central and peripheral nervous systems. Supplementation with B vitamins plays a role in sustaining neurological health. This means the preparation helps support vital processes that keep nerve pathways working optimally. Additionally, components like Cyanocobalamin assist in essential erythropoietic activity, directly supporting the production of healthy blood cells. It is typically used by adults seeking nutrient repletion or supplementary metabolic support.

What side effects are possible with Terneurine?

Possible Side Effects and Safety Information

The safety profile of Terneurine, a B-complex vitamin combination (B1, B6, B12), is classified in regulatory documents according to the likelihood and location of adverse reactions.

Frequency-Classified Adverse Reactions

Adverse reactions are formally grouped by frequency. Common effects documented in official labeling typically include mild and transient symptoms such as nausea, vomiting, diarrhea, abdominal discomfort, headache, and dizziness. Skin reactions, including rash or hives, are also classified in official documents.

System-Organ Classification

The documented effects are grouped into System-Organ Classes (SOCs) in regulatory texts. The primary affected systems include Gastrointestinal Disorders (e.g., nausea, diarrhea), Nervous System Disorders (e.g., headache, dizziness), and Immune System Disorders (e.g., allergic reactions).

Serious Adverse Reactions and Duration Patterns

Serious adverse reactions documented in official sources include rare events such as anaphylactic shock, which is primarily associated with injectable administration. A specific risk is the development of severe peripheral neuropathy, which regulatory data explicitly links to prolonged use of very high doses of the Pyridoxine (B6) component.

Safety Constraints and Special Populations

Official safety notes define constraints for specific scenarios. High-dose Pyridoxine (B6) is documented to reduce the efficacy of the medicine Levodopa. Furthermore, population-specific statements exist for pregnant and breastfeeding women, noting that high-dose B6 use is associated with potential risk to the newborn or suppression of lactation. Use is formally contraindicated in individuals with known hypersensitivity to the components, including cobalt sensitivity (related to B12). The safety profile is structured to emphasize that risk is often duration- and dose-dependent.

Overdose and Emergency Response

Overdose Manifestations and Emergency Action

The official regulatory documentation for Terneurine identifies the risk of severe, potentially life-threatening overdose manifestations that necessitate immediate medical intervention. Documented overdose presentations often involve significant central nervous system (CNS) effects, ranging from profound drowsiness, stupor, or coma to states of convulsions, restlessness, and muscle rigidity. Autonomic symptoms such as mydriasis (pupil dilation), fever, and vomiting are also officially documented.

The most critical documented risks are cardiovascular events. These include life-threatening arrhythmias like Torsades de pointes, severe hypotension, and the potential for cardiac arrest. Other serious outcomes listed in regulatory documents include respiratory depression and the development of Serotonin Syndrome, a systemic crisis.

Due to the severity of these documented risks, regulatory authorities explicitly mandate that immediate medical attention be sought for any suspected overdose. Emergency services must be contacted immediately. The official profile states that no specific antidote is known. Management, therefore, relies on symptomatic and supportive treatment, including necessary measures for gastric decontamination. Hospital monitoring is required for an extended period because of the risk of delayed cardiotoxicity. The elderly population is noted to be at increased risk for CNS manifestations, including confusion and agitation.

Therapeutic Uses of Terneurine

Terneurine, which contains the active ingredient clomipramine, is applied in addressing a specific condition characterized by periods of heightened symptoms known as Obsessive-Compulsive Disorder (OCD).

Clomipramine is applied in addressing symptoms related to physical discomfort such as obsessions and compulsions that interfere with daily functioning. Its use is considered relevant for easing symptoms related to heightened physiological activity.

This therapeutic application assists with managing symptoms that interfere with daily functioning, including recurrent, unwanted thoughts and the need to perform repetitive behaviors. The treatment supports patients during episodes of heightened discomfort and contributes to easing the overall symptom load. The compound is considered relevant in clinical settings that involve acute or unstable symptom patterns.

“The treatment helps maintain a sense of stability when symptoms are more noticeable.”

Quick Fact: Supports Management of Obsessions and Compulsions

Eligibility and Restrictions for Use

Who Can and Cannot Use Terneurine?

The eligibility for using Terneurine (Clomipramine) is strictly defined by regulatory authorities based on age, coexisting medical conditions, and concurrent therapies.

Eligibility Scope Regulatory Status
Populations Allowed Approved for adults and pediatric patients aged 10 years and older for Obsessive-Compulsive Disorder (OCD).
Populations Contraindicated Patients with known hypersensitivity to clomipramine or other tricyclic antidepressants; individuals taking Monoamine Oxidase Inhibitors (MAOIs); patients in the acute recovery period following a myocardial infarction.

Age-Related Eligibility Rules: Safety and efficacy are not established for children younger than 10 years. Use requires caution in older adults (65+).

Condition-Specific Eligibility: Caution is warranted for patients with a history of seizures, certain cardiovascular disorders, or severe renal impairment. Severe hepatic disease is an absolute contraindication.

Pregnancy and Lactation: During pregnancy (Category C), use is generally not recommended unless the benefit outweighs the risk. Nursing mothers should either discontinue the drug or discontinue breastfeeding as the drug is excreted in human milk.

Connection to the overall eligibility profile: Official regulatory documents define who can and cannot use the medicine primarily through absolute contraindications, while setting specific age limitations and mandating conditional use for patients with pre-existing cardiac or organ conditions.

What should I know about interactions with other medicines?

Terneurine's active ingredient, Clomipramine, has officially documented interactions that structure its regulatory profile. The highest restriction level involves formal contraindications, notably with Monoamine Oxidase Inhibitors (MAOIs), which must not be co-administered due to the significant risk of Serotonin Syndrome. A mandatory separation period of at least 14 days is required when switching between these agents.

Co-administration with Pimozide and Thioridazine is also formally prohibited because of the documented risk of QTc interval prolongation.

Documented Pharmacokinetic Interactions

Certain medicinal products inhibit the metabolic enzymes CYP2D6 or CYP1A2 (e.g., Fluvoxamine, Cimetidine). These pharmacokinetic interactions are documented to cause a significant increase in Terneurine's plasma concentrations by reducing its clearance.

Pharmacodynamic and Population Notes

The label also identifies pharmacodynamic interactions with CNS depressants (including alcohol) and anticholinergic drugs, which result in additive effects. Furthermore, regulatory documents specify that elderly patients may experience higher steady-state plasma concentrations due to reduced clearance, which officially heightens the potential for interaction risk in this population.

Mechanism of Action

The mechanism of this combination product (Thiamine B1, Pyridoxine B6, and Cyanocobalamin B12) is based on co-factor activity essential for cellular metabolism and structural processes.

Metabolic Cofactor Support for Neuronal Energy

This domain focuses on the role of B1 as a cofactor (Thiamine Pyrophosphate, TPP) for key enzymes like Pyruvate Dehydrogenase ( PDH) and alpha-Ketoglutarate Dehydrogenase (alpha-KGDH). By facilitating the TCA cycle, the mechanism supports the production of ATP, thereby supporting the metabolic requirements for continuous nerve impulse transmission.

Cofactor Role in Nerve Fiber Structure and Synthesis

This mechanism centers on the function of B12 (as Methylcobalamin) and B6 as cofactors in the Methionine cycle. This process is essential for generating S-adenosylmethionine ( SAMe), which is crucial for the synthesis of myelin sheath phospholipids. The resulting physiological effect involves co-factor support for nerve fiber structural synthesis and preservation.

Modulation of Neurotransmitter Synthesis

This domain is defined by the cofactor role of B6 (Pyridoxal 5-Phosphate, PLP) for Glutamic Acid Decarboxylase ( GAD). By promoting the biosynthesis of the inhibitory neurotransmitter GABA, the mechanism promotes the physiological basis for damping neural excitability and regulating signal transmission.

Dosage and Administration Information

Terneurine, a proprietary name for a combination of B vitamins, is typically prescribed to treat deficiencies of Thiamine (Vitamin B1), Pyridoxine (Vitamin B6), and Cyanocobalamin (Vitamin B12). The proper use of this medication depends heavily on the specific deficiency being treated, the formulation (e.g., oral tablet or injection), and the individual patient's medical condition.

General Administration Guidelines

  • Prescriber's Directions: Always follow the dosage and duration of treatment as directed by a healthcare provider. The prescribed regimen is based on a professional assessment of the patient's nutritional status and underlying cause of deficiency.
  • Oral Formulations: If taking an oral form, the tablets should generally be swallowed whole with water. They can be taken with or without food unless otherwise instructed. Consistency is key, so take doses at the same time each day.
  • Dosage: Doses vary widely. For instance, the Recommended Dietary Allowance (RDA) for adults is 2.4 mug of Vitamin B12 and 1.3 mg of Vitamin B6, but therapeutic doses for deficiency treatment are substantially higher to replenish stores.
Component Adult RDA Therapeutic Doses (Example)
Vitamin B12 (Cyanocobalamin) 2.4 mug Up to 1000 mug daily or monthly (for deficiency)
Vitamin B6 (Pyridoxine) 1.3 mg Higher doses may be used but have an established Upper Limit of 100 mg/day

Missed Dose

If a dose is missed, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not take two doses at once to make up for a missed one.

Important Considerations

Inform your doctor of all other medications and supplements you are taking, as they may interact with B vitamins. Do not stop using the medication without consulting your healthcare provider, even if symptoms improve.

Recent Clinical Evidence

Research evidence / Overview of Studies for Terneurine

Evidence for Use in Obsessive-Compulsive Disorder (OCD)

The research examined the active ingredient, Clomipramine, in placebo-controlled clinical trials for Obsessive-Compulsive Disorder (OCD). These studies included patient groups diagnosed with OCD, such as adults and pediatric patients (ages 10 to 17). Trials monitored outcomes related to symptom intensity, using specialized tools like the Yale-Brown Obsessive Compulsive Scale (YBOCS).

Research describes that these studies focused on measuring the change in score on severity scales over the study period. While studies monitored how symptom intensity evolved over the short term, the primary trials often had follow-up durations that were limited (typically 8 to 10 weeks). Consequently, long-term observation of outcomes is not fully characterized, and limited information exists for long-term patient results.


Evidence for Use in Nutrient Repletion and Nerve Support

The evidence base for the B-vitamin combination was observed in Randomized Controlled Trials (RCTs), systematic reviews, and observational studies. This research has explored the combination’s role in managing outcomes related to systemic or functional imbalance, such as nutrient repletion and neuro-physiological support.

Studies monitored changes in blood biomarker levels (e.g., serum vitamin levels) and functional assessments, such as cognitive tests and nerve conduction. Evidence related to functional outcomes is data are still emerging and findings were mixed. Evidence quality varies across studies due to heterogeneity in formulations, and the results apply only to the specific populations and formulations examined.


Research Gaps and Patient Populations

Research has explored long-term outcomes in both clinical tracks, but sustained effects are not fully established. Evidence was evaluated in specific patient groups, including older adults for nutrient repletion. However, data for certain groups remain insufficient.

Overall, research provides context but does not determine whether an individual will respond similarly. Comparative evidence between different formulations is also lacking, and research provides context, not a complete picture of outcomes across all patient scenarios.

Frequently Asked Questions (FAQ)

Common questions about Terneurine (FAQ)


Q: Is Terneurine considered a narcotic or controlled substance?

According to regulatory documentation, the active ingredients in Terneurine (Thiamine, Pyridoxine, and Cyanocobalamin) are not classified as controlled substances under the US regulatory framework. The product is generally viewed as a nutritional supplement or B-complex vitamin, although classification details may vary by region.


Q: How long does Terneurine typically stay in a person's system?

Official product information on the B12 component indicates that its concentration in the plasma typically peaks within one hour following intramuscular injection. A significant portion of the dosage is typically described as being excreted in the urine, often within 8 to 48 hours of administration.


Q: Is it normal to feel tired when starting Terneurine?

Regulatory literature includes general statements that fatigue is an effect to watch for when taking B-complex vitamins. However, regulatory information also notes that excessive tiredness or weakness can be a symptom related to deficiencies, or, in rare cases, a sign that requires prompt assessment.


Q: Can Terneurine cause changes in my weight?

General weight gain is not listed as a common effect of this medication. Official information documents that rapid weight gain may be a possible sign of a serious adverse reaction, such as pulmonary edema or congestive heart failure, which requires prompt medical attention.


Q: Does taking Terneurine affect my ability to drive or operate machinery?

Regulatory documents indicate that nervous system effects, such as dizziness and headache, are possible common side effects. These effects may indirectly influence the physical ability required for tasks such as driving or operating machinery.


Q: Where can I find the official regulatory information sheet for Terneurine?

Official information sheets for medications are available on authoritative governmental regulatory websites. The most current product information is typically available on authoritative government sites like the FDA's DailyMed or can be obtained by contacting the manufacturer directly.


Q: Is Terneurine known to interact with birth control pills?

Studies have examined the relationship between B vitamins and hormonal contraceptives. Regulatory literature on B-vitamin depletion indicates that the use of oral contraceptives may lead to lower B vitamin levels, which is a factor to consider during supplementation.


Q: Do regulatory bodies classify Terneurine as a high-risk medication?

Terneurine is primarily classified by regulatory bodies as a B-complex vitamin and nutritional supplement. The product does not typically appear on formal high-risk medication lists that apply to controlled substances or specific high-alert drugs.


Q: Is there a generic version of Terneurine available?

The active ingredients—Thiamine, Pyridoxine, and Cyanocobalamin—are widely known generic vitamin components. These components are commonly available in various generic B-complex products and individual generic forms.


Q: Does Terneurine have the potential to interact with caffeine?

According to official regulatory warnings, no specific interaction between caffeine consumption and the B-complex product is typically documented. Disclosure of all concurrent intake to a healthcare provider is generally recommended.


Q: How is Terneurine different from similar medications I see online?

One key difference is the various dosage forms available, including an injectable solution. This injectable preparation is typically reserved for parenteral use in cases of severe deficiency or malabsorption, such as pernicious anemia, distinguishing it from simple oral supplements.


Q: Will I feel the effects of Terneurine immediately after taking it?

Official product information indicates that the B12 component is absorbed quickly into the body. Following intramuscular injection, the plasma level of Vitamin B12 typically reaches its peak within one hour, showing immediate absorption.


Q: Can Terneurine interact with over-the-counter pain relievers like ibuprofen?

Regulatory information requires patients to inform their healthcare provider about all over-the-counter (OTC) medicines they use. While major interactions with common OTC pain relievers (like ibuprofen) are not often highlighted, general disclosure of all medications to a healthcare provider is typically recommended.


Q: Does Terneurine have any known interactions with herbal supplements?

Regulatory guidance requires patients to inform their healthcare provider about all herbal products and other supplements they are taking. This practice is required in regulatory guidance due to the potential for unknown interactions or cumulative effects.


Q: Are there any specific foods or drinks that should be avoided while on Terneurine?

According to the official administration guidelines, the medication can generally be taken with or without food. Specific regulatory warnings to avoid non-alcoholic foods or drinks are generally absent from the product documentation.


Q: Can older adults typically use Terneurine safely?

Regulatory documentation indicates that use in older adults is a population that warrants careful assessment. This is based on indications that reduced clearance in this population may lead to higher plasma concentrations of one of the original components.


Q: Is Terneurine usage described as safe for people with kidney problems?

Regulatory documents warrant caution for use in patients with severe renal impairment (kidney problems). This indication means that professional assessment is warranted before its use in this population.


Q: Is Terneurine a long-term treatment or is it usually for a short time?

Official documentation explicitly links the use of high doses of the B6 component over a prolonged duration to a documented risk of severe peripheral neuropathy. The appropriate treatment length is determined by a healthcare provider.


Q: What is the general expectation for how long it takes to see the full effect of Terneurine?

While the B12 component is rapidly absorbed and reaches a plasma peak within one hour of injection, the overall time to see the full clinical effect can vary. The time required for full therapeutic effect in deficiency treatment depends greatly on the individual patient's baseline condition.


Q: What should be done if an allergic reaction is suspected after taking Terneurine?

Serious adverse reactions, such as anaphylaxis (a severe allergic reaction), are documented in official sources. The regulatory protocol for any suspected severe reaction is to seek immediate emergency medical services or guidance from a poison control center.


Q: What is the purpose of the different strengths or dosages of Terneurine?

Doses of the B vitamins in this product vary widely, from the Recommended Dietary Allowance (RDA) to higher therapeutic doses. The purpose of these higher strengths is to treat specific vitamin deficiencies and replenish existing vitamin stores.


Q: Can Terneurine be taken alongside vitamin supplements?

Regulatory information cautions that this B-complex product may potentially interact with other vitamins or minerals. For this reason, disclosure of all supplements used to a healthcare provider is consistent with regulatory guidance.


Q: What are the main reasons Terneurine might be stopped by a healthcare provider?

Regulatory documentation indicates that discontinuation may be required if severe adverse reactions occur (e.g., severe peripheral neuropathy) or when the physician determines the treatment goal has been achieved.


Q: Is Terneurine recommended for use in children or teenagers?

Recommended dietary allowances for B-vitamin supplementation in children and teenagers are outlined in nutritional and pediatric guidelines. The necessity and appropriate dosage for deficiency treatment in these populations are determined by a healthcare professional.


Q: Can Terneurine be crushed or split for easier consumption?

Regulatory documentation for similar B-complex oral tablets explicitly states the medication should be swallowed whole. The documentation indicates that the tablets should not be split, crushed, or chewed unless a healthcare professional provides specific instruction.


Q: What are the official guidelines regarding maximum treatment duration for Terneurine?

Regulatory documents advise that the treatment duration should be determined by a healthcare provider. Regulatory documents emphasize that the appropriate treatment duration must be determined by a healthcare provider, especially due to the documented risk of peripheral neuropathy associated with prolonged use of high doses of the Vitamin B6 component.


Q: Does taking Terneurine at night versus the morning make a difference?

Patient literature suggests taking B-complex vitamins in the morning. This practice is often recommended to align with the vitamins' role in energy metabolism and to potentially avoid mild stimulatory effects from the B12 component that could interfere with sleep.


Q: What is the difference between Terneurine and similar drugs in the same class?

The differences between Terneurine and similar B-complex products often involve the dosage form available (oral vs. injectable solution) and the specific amounts of the active B vitamins included. These variations allow prescribers to choose products for nutrient maintenance versus therapeutic deficiency treatment.


Q: Are there specific monitoring tests recommended while a person is on Terneurine?

Regulatory documents indirectly indicate the importance of monitoring, particularly blood work, due to the role of B12 in blood cell production. This monitoring may be suggested because B-vitamin levels can also be affected by other factors.

How should Terneurine be stored and disposed of?

How to Store and Dispose of Terneurine

Terneurine must be stored according to regulatory requirements to ensure its stability.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature (20 C to 25 C), away from excess heat.
Environment The medicine must be protected from moisture; do not store it in the bathroom.
Container Keep the medication in its original container, ensuring the lid remains tightly closed.

Handling and Disposal

Store Terneurine out of the sight and reach of children, always securing the container with a locked safety cap.

Disposal of unused or expired product must follow official guidelines. The preferred method is using a drug take-back program. If this is unavailable, mix the medicine with an undesirable substance (such as dirt) in a sealed bag and dispose of it in the household trash. Do not flush this medication down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Terneurine found in:

A-Z Index: